{"id":389192,"date":"2023-06-22T00:00:00","date_gmt":"2023-06-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2023-biopharma-psoriasis-access-reimbursement-us-2023\/"},"modified":"2026-03-31T10:32:47","modified_gmt":"2026-03-31T10:32:47","slug":"acreim0017-2023-biopharma-psoriasis-access-reimbursement-us-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2023-biopharma-psoriasis-access-reimbursement-us-2023\/","title":{"rendered":"Psoriasis | Access &#038; Reimbursement | US | 2023"},"content":{"rendered":"<p>Established targeted therapies, such as Janssen\u2019s interleukin (IL)-12\/23 inhibitor Stelara, AbbVie\u2019s tumor necrosis factor-alpha (TNF-\u03b1) inhibitor Humira, and Novartis\u2019s IL-17A inhibitor Cosentyx, dominated the U.S. psoriasis biologics market. However, with the approval of novel, more-effective therapies, the treatment landscape is changing and the competition for favorable coverage from MCOs is intensifying. Amgen\u2019s oral PDE-4 inhibitor Otezla, Eli Lilly\u2019s IL-17 inhibitor Taltz, and Janssen\u2019s IL-23 inhibitor Tremfya have successfully carved out space in the treatment algorithm. Skyrizi, AbbVie&#8217;s latest IL-23 inhibitor, is closing in on the established market leaders and has dominated earlier-to-market biologics. Competition is further intensifying with the recent entry of Sotyktu (BMS\u2019s oral TYK2 inhibitor) and the first biosimilar of Humira, along with the anticipated launches of UCB\u2019s Bimzelx (an IL-17 A\/F dual inhibitor), and other biosimilars challenging Humira\u2019s dominance. This report will help marketers navigate this challenging market access environment with valuable insights on how payer coverage policies affect dermatologists\u2019 prescribing.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>Among commercially insured psoriasis patients, what percentage receive newer targeted agents, and which targeted therapies do physicians perceive to perform best on specific clinical and market access factors?<\/li>\n<li>How do payers cover biosimilar versions of infliximab (Pfizer\u2019s Inflectra, Merck\u2019s Renflexis, and Amgen\u2019s Avsola), and how do physicians expect to prescribe these biosimilars?<\/li>\n<li>What are physician perceptions of emerging therapies such as bimekizumab? How do payers anticipate covering these agents?<\/li>\n<li>For psoriasis drugs with similar efficacy and safety, what economic factors most influence favorable coverage in MCOs&#8217; largest fully insured plans?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.<\/p>\n<p><strong>Key drugs<\/strong>: Humira, Amjevita, Enbrel, Remicade, Inflectra, Renflexis, Avsola, Cimzia, Stelara, Otezla, Cosentyx, Taltz, Siliq, Tremfya, Ilumya, Skyrizi, Bimzelx, Sotyktu<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB<\/p>\n","protected":false},"template":"","class_list":["post-389192","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389192\/revisions"}],"predecessor-version":[{"id":576091,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389192\/revisions\/576091"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}